Aliases:This biomarker is also known as:
- cystatin A (stefin A),
- cystatin AS,
CSTA, or cystatin-A, is a member of the cystatin superfamily, which includes proteins that contain multiple cystatin-like sequences. Some members of the cystatin superfamily are active cysteine protease inhibitors, of which there are three families: type 1 cystatins (stefins), type 2 cystatins, and kininogens. CSTA is a stefin that functions as a cysteine protease inhibitor, forming tight complexes with papain and the cathepsins B, H, and L. Stefins have been proposed as prognostic and diagnostic biomarkers for cancer.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
Studies have demonstrated an inverse relationship between increased cathepsin B expression and decreased CSTA in a variety of human tumors. Studies suggest that CSTA is one of the promising candidate biomarkers for lung cancer and deserves further investigation in lung tumorigenesis.
CSTA belongs to a 9-member panel that provides a quantitative measure of the probability of having lung cancer that goes beyond the histological evaluation of preinvasive lesions. The identified members of the panel are TMSB4X (Thymosin beta-4), Ubiquitin, des-ubiquitin, ACBP, CSTA, Cytochrome C, and MIF.